Repository for Brain Tumor Biomarkers
This study is collecting blood samples from adults with primary or metastatic brain tumors who are receiving radiation therapy at Duke Cancer Center. The goal is to create a collection (repository) of these samples to help researchers understand how certain substances in the blood (circulating biomarkers) are connected to how well radiation therapy works. There are no specific interventions or drugs being tested in this study. You can join if you are 18 years or older and have a confirmed diagnosis of a primary or metastatic brain tumor. The study aims to enroll 300 participants. The main thing they will measure is the number of immune cells in your blood six weeks after you finish radiation therapy. The current recruitment status is unclear.
- Study design
- This is an observational study, meaning researchers will collect information without giving any specific treatments. It plans to include 300 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will measure circulating immune cells in your blood 6 weeks after radiation therapy.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Eugene Vaios, MD MBA · PRINCIPAL_INVESTIGATOR · Duke University Health System (DUHS)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Number of circulating immune cells in peripheral blood6 weeks post radiation therapy
reported as mean +/- standard deviation